A National Institutes of Health-funded study led by a team at the Georgia Institute of Technology and Emory University has shown that an influenza vaccine can produce robust immune responses and be administered safely with an experimental patch of dissolving microneedles.
The method is an alternative to needle-and-syringe immunization; with further development, it could eliminate the discomfort of an injection as well as the inconvenience and expense of visiting a flu clinic.
“This bandage-strip sized patch of painless and dissolvable needles can transform how we get vaccinated,” said Roderic I. Pettigrew, Ph.D., M.D., director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), which funded the study. “A particularly attractive feature is that this vaccination patch could be delivered in the mail and self-administered. In addition, this technology holds promise for delivering other vaccines in the future.”
The researchers received funding through an NIBIB Quantum Grant and from the National Institute of Allergy and Infectious Diseases.
The study, published online June 27, 2017, in The Lancet, was led by Nadine Rouphael, M.D., associate professor of medicine and Mark J. Mulligan, M.D., distinguished professor of medicine, Emory University School of Medicine, in collaboration with Mark R. Prausnitz, Ph.D., Regents Professor and J. Erskine Love Chair in Chemical and Biomolecular Engineering, Georgia Institute of Technology. A team led by Prausnitz designed the dime-sized patch of microneedles used in the study.
The vaccine patch consists of 100 solid, water-soluble needles that are just long enough to penetrate the skin. “The skin is an immune surveillance organ,” Prausnitz said. “It’s our interface with the outside world, so it’s very well equipped to detect a pathogen and mount an immune response against it.”
Adhesive helps the patch grip the skin during the administration of the vaccine, which is encapsulated in the needles and is released as the needle tips dissolve, within minutes. The patch is peeled away and discarded like a used bandage strip.
The researchers enrolled 100 adult participants, dividing them into four random groups: vaccination with microneedle patch given by a health care provider; vaccination with microneedle patch self-administered by the study participant; vaccination with intramuscular injection given by a health care provider; and placebo microneedle patch given by a health care provider. The researchers used an inactivated influenza vaccine formulated for the 2014-15 flu season to inoculate participants other than those in the placebo group.
The researchers found that vaccination with the microneedle patches was safe, with no serious related adverse events reported. Some participants developed local skin reactions to the patches, described as faint redness and mild itching that lasted two to three days.
The results also showed that antibody responses generated by the vaccine, as measured through analysis of blood samples, were similar in the groups vaccinated using patches and those receiving intramuscular injection, and these immune responses were still present after six months. More than 70 percent of patch recipients reported they would prefer patch vaccination over injection or intranasal vaccination for future vaccinations.
No significant difference was seen between the doses of vaccine delivered by the health care workers and the volunteers who self-administered the patches, showing that participants were able to correctly self-administer the patch. After vaccination, imaging of the used patches found that the microneedles had dissolved in the skin, suggesting that the used patches could be safely discarded as non-sharps waste. The vaccines remained potent in the patches without refrigeration for at least one year.
The prospective vaccine technology could offer economic and manufacturing advantages. The manufacturing cost for the patch is expected to be competitive with prefilled syringe costs. The patch, however, can dramatically reduce the cost of vaccination, since self-administration can eliminate the need to have health workers oversee the process. It can be easily packaged for transportation, requires no refrigeration, and is stable.
Prausnitz is co-founder of a company that is licensing the microneedle patch technology. He is an inventor on licensed patents and has ownership interest in companies developing microneedle products, including Micron Biomedical. These potential conflicts of interest have been disclosed and are overseen by Georgia Institute of Technology and Emory University.
The team plans to conduct further clinical trials to pursue the technology’s ultimate availability to patients. They also are working to develop microneedle patches for use with other vaccines, including measles, rubella and polio.
Learn more: Researchers develop microneedle patch for flu vaccination
The Latest on: Microneedle patch
[google_news title=”” keyword=”microneedle patch” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Microneedle patch
- Medicus Pharma Ltd. Announces Proposed Private Placement of Convertible Noteson April 25, 2024 at 7:20 am
Detailed price information for Medicus Pharma Ltd (MDCX-X) from The Globe and Mail including charting and trades.
- Vietnam Advanced Drug Delivery Market Onward and Upward Market Size’s Path to New Heightson April 24, 2024 at 2:01 pm
Request To Download Free Sample of This Strategic Report @ This country research report on Vietnam Market offers comprehensive insights into the market landscape, customer intelligence, and ...
- African clinics to get Gates’ new portable ultrasound techon April 23, 2024 at 1:11 am
ALARMING mortality rates in pregnancy-related complications in remote areas of Africa are likely to be reduced in the wake of unveiling ground-breaking, portable ultrasound technology by the Bill & ...
- Needle-Free Vaccines: Leading Innovation in Drug Deliveryon April 18, 2024 at 2:28 pm
Experts discuss alternative administration roots and why they matter. Megan Livingston, Vice President of Business Development, Jurata Thin Film Inc. Gunilla B. Jacobson, Director of Translational ...
- Stick to Clear Skin: Anti-Acne Patch Market Projected to Boom at 6.5% CAGR by 2034on April 17, 2024 at 6:33 pm
The anti-acne dermal patch market is expected to reach US$ 586.3 million by 2024. The market size is expected to reach US$ 1.1 billion by 2034, projected at a CAGR of 6.5%. The acne bacterium ...
- How microneedling works to boost collagen production for skinon April 16, 2024 at 6:00 pm
Collagen is very important for our skin care, and microneedling is an effective technique that promotes its production. Tiny needles are used in microneedling in a way that skin becomes smooth, firm ...
- Pharmaceutical Drug Delivery Market Upcoming Trends, Size, Key Players, Revenue, Share, and Forecast 2024 to 2032on April 11, 2024 at 4:25 pm
Pharmaceutical Drug Delivery Market”, published by Report Ocean, presents a comprehensive analysis of the product’s/service industry, examining both historical patterns and ...
- The 15 Best Under Eye Masks for Menon April 2, 2024 at 9:10 am
We’ve all had those mornings. Whether it’s after a night of insomnia or an especially wild party, waking up with puffy, swollen eyes, dark raccoon-like circles or dry, saggy bags has happened to all ...
- 50 Effing Brilliant Things Under $30 You'll End Up Using All The Timeon January 17, 2024 at 3:30 pm
There are a ton of unique Amazon finds out there, but this list is the place to turn for all of the brilliant finds that you’ll actually use all of the time. Zero dust-collecting products here. Not ...
via Bing News